Faricimab

Faricimab is a humanized bispecific immunoglobulin G1 (IgG1) antibody that acts through inhibition of two distinct pathways by neutralization of both Ang-2 and vascular endothelial growth factor A (VEGF-A). Ang-2 causes vascular instability and sensitizes blood vessels to the activity of VEGF-A. Ang-2 and VEGF-A synergistically increase vascular permeability and stimulate neovascularization.

By dual inhibition of Ang-2 and VEGF-A, faricimab reduces vascular permeability and inflammation, inhibits pathological angiogenesis and restores vascular stability.

• Neovascular (Wet) AMD: Used for treatment of age-related macular degeneration.
• Diabetic Macular Edema (DME): Used for treatment of DME.
• Macular Edema Secondary to RVO: Used for treatment of macular edema due to retinal vein occlusion.

Ophthalmic (Anti-VEGF)

Bispecific Angiopoietin-2 and VEGF Inhibitor

Faricimab is a humanized bispecific immunoglobulin G1 (IgG1) antibody that acts through inhibition of two distinct pathways by neutralization of both Ang-2 and VEGF-A. Ang-2 causes vascular instability and sensitizes blood vessels to the activity of VEGF-A. Ang-2 and VEGF-A synergistically increase vascular permeability and stimulate neovascularization.

Faricimab reduces vascular permeability and inflammation, inhibits pathological angiogenesis and restores vascular stability through dual inhibition of Ang-2 and VEGF-A.

Adult Dose (Intravitreal):

• Neovascular AMD: First 4 doses: 6 mg (0.05 mL) every 4 weeks, then 6 mg up to every 16 weeks.
• Diabetic Macular Edema (DME): First 4 doses: 6 mg every 4 weeks, then 6 mg up to every 16 weeks.
• Macular Edema Secondary to RVO: 6 mg every 4 weeks.

For intravitreal injection only. Must be administered by a qualified physician experienced in intravitreal injections. Each vial should only be used for the treatment of a single eye.

If you miss a dose, please consult your ophthalmologist.

Side Effects:

• Intravitreal injection-related reactions
• Intraocular inflammation
• Infections
• Increased blood pressure

Precautions:

• Contraindicated in patients with ocular or periocular infections.
• Contraindicated in patients with active intraocular inflammation.
• Contraindicated in patients with known hypersensitivity.
• Monitoring between dosing visits should be scheduled based on patient status and physician's discretion.

Contraindications:

• Ocular or periocular infections
• Active intraocular inflammation
• Hypersensitivity to faricimab or any excipients

Drug Interactions: No known interactions.

Food Interactions: No interactions with food.

Use in Pregnancy: No data from use in pregnant women; caution required.

Use in Lactation: It is not known whether Faricimab is excreted in human milk; caution required.

Pediatric Use: Safety and efficacy not established.

Geriatric Use: In clinical studies, approximately 58% of patients were >=65 years; no significant differences in efficacy or safety with increasing age.

Renal Impairment: No dose adjustment required.

Hepatic Impairment: Safety and efficacy not studied.

Overdose: Limited information on overdose; symptomatic treatment.

Storage: Store at 2-8 degree C. Do not freeze. Keep in original carton to protect from light.

Faricimab